Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function
Phase 2
18+
1 site in KS
What this study is about
This Phase 2 study is testing Metformin Hydrochloride in people with cystic fibrosis. The primary outcome being measured is Change in BK channel gene expression.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Blood Glucose Regulators (Insulin Receptor Agonists)
oral (Oral Tablet)
Primary: Change in BK channel gene expression
Secondary: Change in Quality of Life (CFQ-R), Change in receptor for receptor for advanced glycation end products (RAGE) gene expression, Pharmacokinetics of metformin
Endocrinology, Respiratory